Product Pathways - Cytoskeletal Signaling
Leptomycin B #9676
- Molecular Formula:
- Molecular Weight:
- 540.73 g/mol
Directions for Use
Leptomycin B is supplied as a 200 μM solution in ethanol within a sealed container. Please use a needle and syringe to remove the solution from the vial. All dilutions, except the final dilution, must be performed in ethanol. Final dilutions can be performed in culture media. Working concentrations and length of treatment can vary depending on the desired effect, but 1-20 nM for 3 hours generally inhibits most nuclear export. Soluble and stable in ethanol. Leptomycin B is not stable in DMSO; do not dilute in DMSO.
In order to minimize evaporation, it is recommended that the LMB vial be kept on ice when in use.
Stability Warning: LMB in any quantity is unstable when dried down into a film. Thus, under no circumstances should the solvent be removed from solutions of LMB because rapid decomposition and loss of recoverable material will result.
Western blot analysis of extracts from HeLa cells, untreated (-) or treated with LMB (200 nM, 18 hr ), using p53 (7F5) Rabbit mAb #2527 and β-Actin (13E5) Rabbit mAb #4970.
Confocal immunofluorescent analysis of IGROV-1 cells, treated with LY294002 #9901 (50 μM, 3hr; left), insulin (100 ng/mL, 30 min; middle), or Leptomycin B followed by insulin (20 nM, 3hr and 100 ng/mL, 30 min, respectively; right), using FoxO1 (C29H4) Rabbit mAb #2880 (green). Actin filaments were labeled with DY-554 phalloidin (red).
Leptomycin B (LMB), originally discovered and utilized as a potent anti-fungal antibiotic from Streptomyces sp., has more recently been identified to inhibit nuclear export of proteins and RNA containing a Nuclear Export Sequence (NES) (1). The mechanism behind LMB's potent inhibition is achieved by specifically binding to chromosomal region maintenance (CRM)/exportin 1 protein; CRM1 binds to ribonuclear proteins containing the NES (1,2). LMB has also been reported to inhibit the degredation and subsequently lead to accumulation of p53 within the nucleus (3) and has demontrated specific anti-tumor properties, although toxic, at high doses (1-3).
- Jang, B.C. et al. (2003) J Biol Chem 278, 2773-6.
- Mutka, S.C. et al. (2009) Cancer Res 69, 510-7.
- Hietanen, S. et al. (2000) Proc Natl Acad Sci U S A 97, 8501-6.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.